WMWilhelmine Meeraus

Wilhelmine Meeraus

*This is an algorithmically generated author record based on publicly available information.

Wilhelmine Meeraus has a total of 80 co-authors. Here are the top co-authors by number of shared publications:

  • Sylvia Taylor

    Medical Evidence, Vaccines & Immune Therapies, AstraZeneca, Eastbrook House, Shaftesbury Road, Cambridge, CB2 8DU, UK

    6 shared publications
  • Kaatje Bollaerts

    P95 Clinical and Epidemiology Services, Leuven, Belgium

    3 shared publications
  • Mario Ouwens

    Medical and Payor Statistics, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden

    3 shared publications
  • Wendy Hartig-Merkel

    P95 Clinical and Epidemiology Services, Leuven, Belgium

    3 shared publications
  • Ainara Mira-Iglesias

    Vaccine Research Department, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO) de la Comunitat Valenciana, Salud Pública , Valencia

    2 shared publications
  • Akshat Dwivedi

    P95 Epidemiology and Pharmacovigilance , Leuven

    2 shared publications

Latest Publications

  • Open Access

    Post-COVID-19 Burden of Severe Influenza in England Among Overall Population and High-Risk Groups: Results From the INFORM Study, 2022–2023

    by Wilhelmine Meeraus, Lucy Carty, Sabada Dube, Kathryn Evans, Rachael A. Evans, Ana Goios, Nahila Justo, Yi Lu, Jennifer K. Quint, Sylvia Taylor, et al.

    We describe the burden of severe influenza in England overall, and in risk groups (as defined by age, immunocompromise, and other comorbidities) and those with recent COVID-19. The INFORM (INvestigation oF cOvid-19 Risk among iMmunocompromised populations) cohort uses pseudonymised, routinely collected electronic health records of individuals aged ≥ 12 years from a random 25% sample of England's population (N = 12.1 million). In this analysis, during 1 July 2022 to 30 June 2023, crude incidence rates (IRs) and age- and sex-adjusted IR ratios were estimated for severe influenza outcomes of hospitalisation, intensive care unit (ICU) admission and death. The analyses were repeated for outcomes of severe influenza with recent COVID-19 (< 6 months). The analysis sample comprised 12,075,920 individuals aged ≥ 12 years; 3.9% were immunocompromised. Overall, IRs of severe influenza were 10.51 (hospitalisations), 0.35 (ICU admissions) and 0.73 (deaths) per 10,000 person-years. Of those with influenza hospitalisation, 13.1% had recent COVID-19. Overall, influenza hospitalisation IRs per 10,000 person-years increased with advancing age, from 3.56 for adolescents aged 12-17 years to 58.43 for adults aged ≥ 80 years. Compared with other age groups, among hospitalised individuals, the highest intensity of management occurred in adolescents aged 12-17 years, based on the proportion of influenza hospitalisations that involved ICU admission (6.2%) or mechanical ventilation (3.0%) in this age group. Increased age- and sex-adjusted risk of severe influenza outcomes was observed among individuals with immunocompromise and other comorbidities. Seasonal severe influenza was observed in the general population aged ≥ 12 years in England in 2022-2023, with a disproportionately higher burden recorded in risk groups (as defined by age, immunocompromise, recent COVID-19 and other comorbidities). These data reinforce continued efforts to immunise individuals against seasonal influenza. International Standard Randomised Controlled Trial Number Registry: ISRCTN53375662.


  • Open Access

    Changing Prevalence of Immunocompromising Conditions in Patients Hospitalized with Severe Acute Respiratory Infection in Europe: Insights from the COVIDRIVE Study

    by Wilhelmine Meeraus, Ivana Prokić, J. Gabrielle Breugelmans, Konstantina Chatzikonstantinidou, Eduardo Conde-Sousa, Irma Casas, Wendy Hartig-Merkel, Gerrit Luit Ten Kate, Sandra Manzanares-Laya, Charlotte Martin, et al.

    Background: Immunocompromised individuals are at substantially increased risk of severe acute respiratory infection (SARI), often compounded by inadequate response to vaccination. We assessed the prevalence of immunocompromising conditions (ICs) among hospitalized SARI patients, overall and by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) status, focusing on temporal trends during the coronavirus disease 2019 (COVID-19) pandemic. We hypothesized that IC prevalence among SARS-CoV-2-positive SARI patients may have increased over time due to increasing background rates of SARS-CoV-2 exposure and differential vaccination coverage and efficacy among those with IC. Methods: We conducted a secondary data analysis of 5280 adults (≥ 18 years) hospitalized with SARI, enrolled in the COVIDRIVE study from five hospitals in Belgium, Italy, and Spain (June 2021-May 2023) and tested for SARS-CoV-2 by reverse transcription-polymerase chain reaction (RT-PCR). IC prevalence (including 95% confidence intervals [CIs)] was assessed using two definitions (main and alternative), excluding and including cancer patients. Changes in IC prevalence over time were assessed using linear trend analysis. Results: Among the 5280 SARI cases, IC prevalence by main definition was 13.9% (95% CI: 12.9–14.8) overall, increasing from 8.3% (95% CI: 3.7–15.8) to a peak of 22.0% (95% CI: 17.9–26.4) in Q3 2022; by alternative definition, IC prevalence was 28.8% (95% CI: 27.6–30.0) overall, increasing from 18.8% (95% CI: 11.5–28.0) to a peak of 38.5% (95% CI: 32.7–44.5) in Q2 2023. Among the 1924 SARS-CoV-2-positive cases, IC prevalence by main definition was 14.2% (95% CI: 12.7–15.9) overall, increasing from 3.4% (95% CI: 0.1–17.8) to a peak of 23.8% (95% CI: 17.4–31.1) in Q3 2022; by alternative definition, IC prevalence was 29.6% (95% CI: 27.6–31.7) overall, increasing from 3.4% (95% CI: 0.1–17.8) to a peak of 46.8% (95% CI: 32.1–61.9) in Q2 2023. The larger observed increase in IC prevalence (by both definitions) over time among SARS-CoV-2-positives, relative to SARI patients without SARS-CoV-2, was statistically significant. Conclusions: Immunocompromised individuals represent a high proportion of hospitalized SARI cases, with results suggesting IC prevalence was higher during later periods of the COVID-19 pandemic. As immunocompromised individuals often respond inadequately to vaccination, alternative strategies are needed to better protect this vulnerable group.

  • Open Access

    Precautionary Health Behaviours as Potential Confounders in COVID-19 Vaccine Effectiveness Studies

    by Chloé Wyndham-Thomas, Leonie de Munter, Kok Yew Ngew, Sanskruti Gaikwad, Konstantina Chatzikonstantinidou, Antonio Carmona, Charlotte Martin, Gerrit Luit Ten Kate, Nicolas Praet, Wilhelmine Meeraus, et al.

    Background/Objectives: Precautionary health behaviours (PHBs), such as hand-washing or self-isolation, are non-pharmaceutical interventions used to reduce SARS-CoV-2 transmission. We investigated the potential confounding by PHBs of COVID-19 vaccine effectiveness (VE) estimates in a subset of study participants enrolled in id.DRIVE. Methods: The id.DRIVE COVID-19 VE study (formerly COVIDRIVE) is a European multicentre test-negative case–control study estimating COVID-19 VE against hospitalisation due to laboratory-confirmed SARS-CoV-2 in patients with severe acute respiratory infection. All adults (≥18 y) prospectively enrolled between 16 November 2021 and 16 August 2023 at three sites were invited to complete a PHB survey capturing indicators of PHBs in the 3 months preceding admission. Fisher’s exact test with Bonferroni-adjusted threshold was used to measure the level of association between PHB indicators and both COVID-19 vaccine status and SARS-CoV-2 test result. VE estimates were generated with and without adjustment for PHBs. Results: PHBs were modified over time, with higher precautionary attitudes in the first COVID-19 vaccine booster season (2021–2022) compared to the second one (2022–2023). For the first booster season, PHBs were positively associated with exposures (vaccination status) and outcomes (case or control status). Adjusting for PHBs led to a 6 to 9 percentage-point increase in VE estimates. Conversely, no confounding by PHBs was observed in the second booster season. Conclusions: PHBs should be considered a possible confounder of COVID-19 VE studies. Further research is needed to define when PHBs should be integrated into VE models, as the level of confounding may differ according to the study population and the epidemiological context.


  • Open Access

    Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron

    by Wilhelmine Meeraus, Abigail Postema, Christen M. Gray, Andrew Lee, Andre Santa Maria, Bárbara Emoingt Furtado, Eduardo Conde-Sousa, Mario Ouwens, Douglas Andreas Valverde, Clóvis Arns da Cunha, et al.

  • Open Access

    Effectiveness of the AZD1222 vaccine against COVID-19 hospitalization in Europe: final results from the COVIDRIVE test-negative case–control study

    by Leonie de Munter, Wilhelmine Meeraus, Akshat Dwivedi, Marianna Mitratza, Chloé Wyndham-Thomas, Lucy Carty, Mario Ouwens, Wendy Hartig-Merkel, Laura Drikite, Griet Rebry, et al.

    Marketing authorization holders of vaccines typically need to report brand-specific vaccine effectiveness (VE) to the regulatory authorities as part of their regulatory obligations. COVIDRIVE (now id. DRIVE) is a European public–private partnership for respiratory pathogen surveillance and studies of brand-specific VE with long-term follow-up. We report the final VE results from a two-dose primary series AZD1222 (ChAdOx1 nCoV-19) vaccine schedule in ≥18-year-old individuals not receiving boosters. Patients (N = 1,333) hospitalized with severe acute respiratory infection at 14 hospitals in Austria, Belgium, Italy, and Spain were included in the test-negative case–control study in 2021–2023. Absolute VE was calculated using generalized additive model (GAM), generalized estimating equation (GEE), and spline-based area under the curve (AUC, measuring VE up to 6 months after the last dose of AZD1222). Overall VE (against coronavirus disease 2019 [COVID-19] hospitalization) of an AZD1222 primary series was estimated as 65% using GEE (95% confidence interval [CI]: 52.9–74.5), and 69% using GAM (95% CI: 50.1–80.9) over the 22-month study period (comparator group: unvaccinated patients). The AUC of the spline-based VE estimate was 74.1% (95% CI: 60.0–88.3). VE against hospitalization in study participants who received their second AZD1222 dose 2 months or less before hospitalization was 86% using GEE (95% CI: 77.8–91.4), 93% using GAM (95% CI: 67.2–98.6). During this study period, where mainly the severe acute respiratory syndrome coronavirus 2 Omicron variant was circulating, a two-dose primary series AZD1222 vaccination conferred protection against COVID-19 hospitalization up to at least 6 months after the last dose.


  • Open Access

    COVID-19 vaccine booster doses provide increased protection against COVID-19 hospitalization compared with previously vaccinated individuals: Interim findings from the REFORCO-Brazil real-world effectiveness study during Delta and Omicron

    by Wilhelmine Meeraus, Anke L. Stuurman, Ilgaz Durukal, Eduardo Conde-Sousa, Andrew Lee, André Santa Maria, Bárbara Emoingt Furtado, Mario Ouwens, Christen M. Gray, Douglas Andreas Valverde, et al.


  • Open Access

    Protection against COVID-19 hospitalisation conferred by primary-series vaccination with AZD1222 in non-boosted individuals: first vaccine effectiveness results of the European COVIDRIVE study and meta-regression analysis

    by Wilhelmine Meeraus, Leonie de Munter, Christen M. Gray, Akshat Dwivedi, Chloé Wyndham-Thomas, Mario Ouwens, Wendy Hartig-Merkel, Laura Drikite, Griet Rebry, Antonio Carmona, et al.


  • Open Access

    Identification of an Optimal COVID-19 Booster Allocation Strategy to Minimize Hospital Bed-Days with a Fixed Healthcare Budget

    by Ritika Kapoor, Baudouin Standaert, Edmund J. Pezalla, Nadia Demarteau, Kelly Sutton, Eszter Tichy, George Bungey, Sofie Arnetorp, Klas Bergenheim, Duncan Darroch-Thompson, et al.

    Healthcare decision-makers face difficult decisions regarding COVID-19 booster selection given limited budgets and the need to maximize healthcare gain. A constrained optimization (CO) model was developed to identify booster allocation strategies that minimize bed-days by varying the proportion of the eligible population receiving different boosters, stratified by age, and given limited healthcare expenditure. Three booster options were included: B1, costing US $1 per dose, B2, costing US $2, and no booster (NB), costing US $0. B1 and B2 were assumed to be 55%/75% effective against mild/moderate COVID-19, respectively, and 90% effective against severe/critical COVID-19. Healthcare expenditure was limited to US$2.10 per person; the minimum expected expense using B1, B2, or NB for all. Brazil was the base-case country. The model demonstrated that B1 for those aged 2 for those ≥70 years were optimal for minimizing bed-days. Compared with NB, bed-days were reduced by 75%, hospital admissions by 68%, and intensive care unit admissions by 90%. Total costs were reduced by 60% with medical resource use reduced by 81%. This illustrates that the CO model can be used by healthcare decision-makers to implement vaccine booster allocation strategies that provide the best healthcare outcomes in a broad range of contexts.